Safe Study of Dendritic Cell (DC) Based Therapy Targeting Tumor Stem Cells in Glioblastoma

Inclusion Criteria: * Accessible volume and quality of tumor tissue for vaccine production * MRI after surgery with minimal tumor remnant. * Between 18 and 70 years of age. * Must have histologically confirmed glioma grade IV, and a candidate for combined radiation therapy and chemotherapy ("Stupps regimen"). * Must be ambulatory with a ECOG performance status 0 or 1. * A minimum 4 weeks must have elapsed between the end of glucocorticoid treatment and beginning of vaccination. * Signed informed consent and expected cooperation of the patients for the treatment and follow up must be obtained and documented. Exclusion Criteria: * Tumor in a localization where a modest increase in size due to reactive oedema may have a large impact on patients neurological condition. * Large tumor remnant after surgery. * History of prior malignancy other than glioma, with the exception of curatively treated basal cell or squamous cell carcinoma of the skin and ca. cervicis stage IB. * Chronic active infection requiring antibiotic therapy. * Significant cardiac or other medical illness that would limit activity or survival, such as severe congestive heart failure, unstable angina, or serious cardiac arrhythmia. * Prior splenectomy. * Glucocorticoid treatment not possible to terminate due to autoimmune disease or increased intracranial pressure. * Adverse reactions to vaccines such as asthma, anaphylaxis or other serious reactions. * History of immunodeficiency or autoimmune disease such as rheumatoid arthritis, systemic lupus erythematosus, scleroderma, polymyositis- dermatomyositis, juvenile onset insulin dependent diabetes, or a vasculitic syndrome. * Chemotherapy or other potentially immune-suppressive therapy that has been administered within 4 weeks prior to vaccination. * Pregnancy or lactation. * Any reason why, in the opinion of the investigator, the patient should not participate.